Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P15918
UPID:
RAG1_HUMAN
Alternative names:
RING finger protein 74
Alternative UPACC:
P15918; E9PPC4; Q8IY72; Q8NER2
Background:
V(D)J recombination-activating protein 1, also known as RING finger protein 74, plays a pivotal role in the immune system's development. It catalyzes the DNA cleavage phase during V(D)J recombination, essential for the diverse repertoire of immunoglobulin and T-cell receptor genes in B and T-lymphocytes. Its activity involves DNA-binding, cleavage, and interaction with histone H3, influencing chromatin structure for effective gene rearrangement.
Therapeutic significance:
The protein's malfunction is linked to severe immunodeficiencies, including Combined cellular and humoral immune defects with granulomas, Severe combined immunodeficiency, Omenn syndrome, and Alpha/beta T-cell lymphopenia. Understanding the role of V(D)J recombination-activating protein 1 could open doors to potential therapeutic strategies for these conditions.